Athanasios Kartalis

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Relation of coronary artery ectasia to diabetes mellitus

Aristides Androulakis, Athanasios Kartalis, Pavlos Stougiannos et al. · The American Journal of Cardiology · 2004 · 56 citations

Medicine, Cardiology, Internal Medicine +12

Varicose Veins are Common in Patients with Coronary Artery Ectasia. Just a Coincidence or a Systemic Deficit of the Vascular Wall?

A. Androulakis, Andreas Katsaros, Athanasios Kartalis et al. · European Journal of Vascular and Endovascular Surgery · 2004 · 53 citations · Full text

Medicine, Anatomy, Cardiology +7